Posts tagged SGYP


Synergy Pharmaceuticals Inc.: Analyst Questions Whether Label Expansion for Trulance Will Prove to Be a “Meaningful” Driver

Ahead of the fourth quarter showcase from Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) anticipated March 7th, first …

Synergy Pharmaceuticals Inc (SGYP) Savvy Leadership Turnover and Upcoming Trulance Approval in IBS-C Have This Bull Confident

H.C. Wainwright’s Ram Selvaraju commends new CEO Troy Hamilton’s strong background in the biotech-verse and roots for Trulance as a long-term winner in the competitive IBS-C playing field.

Tim Chiang Upbeat on These Two Biotech Players Circling FDA Approvals in 2018: Synergy Pharmaceuticals Inc., Progenics Pharmaceuticals

As SGYP and PGNX both await potential FDA approvals this year, BTIG’s Tim Chiang shares his positive two cents on these drug makers he believes present meaningful upside potential.

Synergy Pharmaceuticals (SGYP) Shares Pop on New CEO Pick

Shares in innovative biopharma Synergy Pharmaceuticals Inc (NASDAQ:SGYP) are rising 3% to $2.06 in today’s …

With FDA Approvals in Sight, Will Synergy Pharmaceuticals and Agile Therapeutics Skyrocket as H.C Wainwright Predicts?

H.C. Wainwright spotlights 280% upside potential for Synergy and close to 111% upside potential for Agile ahead of FDA decisions.

Synergy Pharmaceutical (SGYP) on Sale Ahead of Upcoming PDUFA Date

Shares in gastrointestinal biopharma Synergy Pharmaceuticals Inc (NASDAQ:SGYP) are plunging by 30% this week, following the …

BTIG’s Take on Synergy Pharmaceuticals Inc (SGYP) and Transenterix Inc (TRXC)

Two healthcare companies with recently approved and much-hyped products- but which one makes a compelling …

Synergy Pharmaceuticals Inc (SGYP): Analyst Makes Bullish Case for Robust Value in Trulance Asset

Canaccord forecasts DTC marketing could be big for SGYP’s Trulance next year, in footsteps of rival Linzess.

Show More